Lojuxta lomitapide regulatory update

Germany's Federal Joint Committee (G-BA) said in a preliminary assessment that Lojuxta lomitapide from Aegerion has "no additional benefit" to treat homozygous familial hypercholesterolemia (hoFH). G-...